From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
U.S. Food and Drug Administration Approves ABRAXANE® in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
-Approval Based on MPACT Study of ABRAXANE in Combination with Gemcitabine Demonstrating a Clinically Meaningful Increase in Overall Survival- -First New Treatment Approved for Metastatic Adenocarcinoma of the Pancreas in Nearly 8 Years-
NIH Awards HTG Molecular Additional $1.01M to Continue Development of Targeted Sequencing Product Concept
TUCSON, AZ–(Marketwired – Sep 4, 2013) – The National Human Genome Research Institute of the National Institutes of Health issued a Notice of Award granting a Phase II SBIR award of $1.01 million for HTG Molecular Diagnostics to continue the Nuclease Probe Mediated Sequencing Project (HTG EdgeSeq). The HTG EdgeSeq program will develop targeted sequencing […]
Phoenix, AZ – September 5, 2013 – Mission3, visionaries in cloud-based software for the Life Sciences industry, today announced it has earned the rank as the 823 fastest growing private company on the Inc. 5000 2013 list. Mission3 realized a 3 year revenue growth of 546%. This list represents the most comprehensive look at […]
Tucson, AZ, September 4, 2013— Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with data storage and IT infrastructure industry leader EMC Corporation (EMC) to offer a highly scalable and flexible solution to store and archive medical images as part of the VENTANA […]
- Women’s Health Moves Mainstream – Rapid Growth Meets Underserved Market
- STEM Summit 2020
- The MedTech Conference
- 10/05/2020 - 10/07/2020
- Arizona Wellbeing Commons 2020
- AZBioPEERS: Leveraging the contacts you made during AZBW